Correspondence 0001213900-23-003406 from NewcelX Ltd. (NCEL)

NewcelX Ltd.
Date: Jan. 18, 2023 · CIK: 0001783036 · Accession: 0001213900-23-003406

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-269220

Date

January 20, 2023

Author

Not clearly detected

Form

CORRESP

Company

NewcelX Ltd.

Letter

NLS Pharmaceutics Ltd.

The Circle 6

8058 Zurich, Switzerland

January 18, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

RE: NLS Pharmaceutics Ltd. (CIK 0001783036)

Registration Statement No. 333-269220 on Form F-3 (the “Registration Statement”)

Ladies and Gentlemen:

NLS Pharmaceutics Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on January 20, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant understands that the Securities and Exchange Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the Registration Statement.

Very truly yours,
NLS PHARMACEUTICS LTD.

Show Raw Text

CORRESP
1
filename1.htm

NLS Pharmaceutics Ltd.

The Circle 6

8058 Zurich, Switzerland

January
18, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

    RE:
    NLS Pharmaceutics Ltd. (CIK 0001783036)

    Registration Statement No. 333-269220 on Form F-3 (the “Registration Statement”)

Ladies and Gentlemen:

NLS Pharmaceutics Ltd. (the “Registrant”)
hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities
Act of 1933, as amended (the “Securities Act”), so that it may become effective on January 20, 2023, at 4:00 p.m.,
Eastern Time, or as soon thereafter as is practicable.

The Registrant understands that
the Securities and Exchange Commission will consider this request for acceleration of the effective date of the Registration Statement
as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act and the Securities Exchange
Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the Registration Statement.

    Very truly yours,

    NLS PHARMACEUTICS LTD.

    By:
     /s/ Chad Hellmann

    Chad Hellmann

    Chief  Financial Officer

SecProbe.io